Furthermore, sorafenib treatment upregulates the expression of phosphorylation-Jun N-terminal kinase and -JUN in human hepatocellular carcinoma Huh-7 cells [78], downregulates the expression of phosphorylation-STAT3 in human oral cancer MC-3 cells [79], and downregulates the expression of the ERK and MEK pathways in HepG2 and PLC/PRF5 cells [80]. This evidence concerns the gene MAP2K7 and lip and oral cavity carcinoma.